JP2025504036A5 - - Google Patents

Info

Publication number
JP2025504036A5
JP2025504036A5 JP2024544968A JP2024544968A JP2025504036A5 JP 2025504036 A5 JP2025504036 A5 JP 2025504036A5 JP 2024544968 A JP2024544968 A JP 2024544968A JP 2024544968 A JP2024544968 A JP 2024544968A JP 2025504036 A5 JP2025504036 A5 JP 2025504036A5
Authority
JP
Japan
Prior art keywords
seq
sequence
nanobody
item
nirgsygntyysr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024544968A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025504036A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/061658 external-priority patent/WO2023147588A2/en
Publication of JP2025504036A publication Critical patent/JP2025504036A/ja
Publication of JP2025504036A5 publication Critical patent/JP2025504036A5/ja
Pending legal-status Critical Current

Links

JP2024544968A 2022-01-31 2023-01-31 親和性が増強された抗ｅｃｍナノボディ－サイトカイン融合体およびその応用 Pending JP2025504036A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263304954P 2022-01-31 2022-01-31
US63/304,954 2022-01-31
PCT/US2023/061658 WO2023147588A2 (en) 2022-01-31 2023-01-31 Enhanced-affinity anti-ecm nanobody-cytokine fusions and their applications

Publications (2)

Publication Number Publication Date
JP2025504036A JP2025504036A (ja) 2025-02-06
JP2025504036A5 true JP2025504036A5 (OSRAM) 2026-02-09

Family

ID=87472533

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024544968A Pending JP2025504036A (ja) 2022-01-31 2023-01-31 親和性が増強された抗ｅｃｍナノボディ－サイトカイン融合体およびその応用

Country Status (6)

Country Link
US (1) US20230295284A1 (OSRAM)
EP (1) EP4473015A2 (OSRAM)
JP (1) JP2025504036A (OSRAM)
CN (1) CN118660909A (OSRAM)
AU (1) AU2023211706A1 (OSRAM)
WO (1) WO2023147588A2 (OSRAM)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116143945A (zh) * 2022-12-09 2023-05-23 浙江大学杭州国际科创中心 一种趋化因子与免疫检查点抑制剂融合表达蛋白及其生产方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020181221A1 (en) * 2019-03-07 2020-09-10 Children's Medical Center Corporation Targeted delivery of immune-modulating vhh and vhh-fusion protein

Similar Documents

Publication Publication Date Title
Zhang et al. Insulin-like growth factor 2 (IGF2)-fused lysosomal targeting chimeras for degradation of extracellular and membrane proteins
CN110913871B (zh) 生成哺乳动物t细胞活化诱导型合成启动子(syn+pro)以改善t细胞疗法
Sun et al. A highlight of recent advances in aptamer technology and its application
EP3765526A1 (en) Cell-mediated exosome delivery
JP2021167329A5 (OSRAM)
CN116134139B (zh) 一种转基因免疫效应细胞及其应用
US20260083866A1 (en) Compositions targeting endothelial cells and uses thereof
CN117186220A (zh) 可结合白介素31的抗体或其抗原结合片段及其制备方法和应用
EP4155404A1 (en) Blood-brain barrier penetrating aptamer, and use thereof
Gras et al. Changes in gene expression pattern of human primary macrophages induced by carbosilane dendrimer 2G-NN16
CN118496355A (zh) 抗血清白蛋白的纳米抗体及其衍生物和应用
CA3180251A1 (en) Cytokine conjugates
Vorobyeva et al. Aptamers against immunologic targets: Diagnostic and therapeutic prospects
CN117964760B (zh) 抗人cll1/cd3的双特异性抗体及其应用
CN119176877B (zh) 一种靶向b细胞cd20的纳米抗体及其应用
CN106928358B (zh) 一种CD105纳米抗体Nb168
JP2005518344A5 (OSRAM)
Mukai et al. IL-12 plays a pivotal role in LFA-1-mediated T cell adhesiveness by up-regulation of CCR5 expression
CN115768788A (zh) Il-2变体
CN120399071A (zh) 一种靶向TfR1的单域抗体及其应用
CN106928360B (zh) 一种CD105纳米抗体Nb68
CN119613545B (zh) 非天然氨基酸修饰的抗ccl5纳米抗体
CN106928355A (zh) 一种CD105纳米抗体Nb184
CN117700555B (zh) 抗cll1的纳米抗体及其相关应用
CN120349409B (zh) Il-18bp纳米抗体及其制备方法与应用